Respiratory Syncytial Virus: Pathology, therapeutic drugs and prophylaxis

dc.date.accessioned2020-04-20T19:47:21Z
dc.date.accessioned2022-10-18T23:08:36Z
dc.date.available2020-04-20T19:47:21Z
dc.date.available2022-10-18T23:08:36Z
dc.date.created2020-04-20T19:47:21Z
dc.date.issued2014
dc.identifierhttp://hdl.handle.net/10533/241642
dc.identifier1131012
dc.identifierWOS:000347753700032
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/4472976
dc.description.abstractHuman Respiratory Syncytial Virus (hRSV) is the leading cause of lower respiratory tract diseases, affecting particularly newborns and young children. This virus is able to modulate the immune response, generating a pro-inflammatory environment in the air
dc.languageeng
dc.relationhttps://doi.org/10.1016/j.imlet.2014.09.006
dc.relation10.1016/j.imlet.2014.09.006
dc.titleRespiratory Syncytial Virus: Pathology, therapeutic drugs and prophylaxis
dc.typeArticulo


Este ítem pertenece a la siguiente institución